Summit Therapeutics PLC (NASDAQ:SMMT – Get Free Report)’s share price hit a new 52-week low during trading on Monday. The stock traded as low as $12.01 and last traded at $12.6040, with a volume of 1,698,713 shares trading hands. The stock had previously closed at $14.15.
Summit Therapeutics News Roundup
Here’s some of the latest news about SMMT:
- Neutral Sentiment: The company’s update confirms the FDA issued a CRL for ivonescimab with platinum-containing chemotherapy in previously treated, locally advanced or metastatic non-small cell lung cancer. Investors will be watching for details on the FDA’s concerns and Summit’s next steps. Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application
- Negative Sentiment: The FDA setback to Summit’s lead cancer-drug application is the main catalyst weighing on SMMT. Reports said shares fell sharply, with one describing them at a 52-week low; the rejection delays the prospect of U.S. approval and adds risk to expectations for ivonescimab. Summit shares drop after US FDA declines to approve lung cancer drug Summit Therapeutics Faces FDA Hurdle For Lead Lung Cancer Drug, Stock Tumbles
Wall Street Analyst Weigh In
SMMT has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating on shares of Summit Therapeutics in a research note on Thursday, October 15th. UBS Group reaffirmed a “neutral” rating on shares of Summit Therapeutics in a research note on Wednesday, September 23rd. Summit Redstone set a $25.00 price objective on Summit Therapeutics in a research note on Wednesday, September 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Summit Therapeutics in a report on Thursday, October 15th. Finally, Citigroup reissued a “market outperform” rating on shares of Summit Therapeutics in a research note on Tuesday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Summit Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $28.61.
Get Our Latest Stock Analysis on Summit Therapeutics
Summit Therapeutics Price Performance
The business’s 50-day moving average is $16.41 and its two-hundred day moving average is $16.14. The firm has a market cap of $10.28 billion, a P/E ratio of -11.99 and a beta of -1.49.
Institutional Trading of Summit Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of SMMT. Fifth Third Bancorp raised its position in shares of Summit Therapeutics by 24.4% in the first quarter. Fifth Third Bancorp now owns 3,732 shares of the company’s stock valued at $71,000 after buying an additional 732 shares in the last quarter. Tidal Investments LLC boosted its stake in shares of Summit Therapeutics by 0.7% in the second quarter. Tidal Investments LLC now owns 121,097 shares of the company’s stock valued at $1,764,000 after buying an additional 783 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Summit Therapeutics by 2.4% in the third quarter. Russell Investments Group Ltd. now owns 42,714 shares of the company’s stock valued at $722,000 after buying an additional 1,021 shares during the period. State Board of Administration of Florida Retirement System boosted its stake in shares of Summit Therapeutics by 1.1% in the third quarter. State Board of Administration of Florida Retirement System now owns 95,254 shares of the company’s stock valued at $1,611,000 after buying an additional 1,025 shares during the period. Finally, GAMMA Investing LLC grew its position in Summit Therapeutics by 61.7% during the third quarter. GAMMA Investing LLC now owns 2,697 shares of the company’s stock worth $46,000 after buying an additional 1,029 shares in the last quarter. Institutional investors own 4.61% of the company’s stock.
Summit Therapeutics Company Profile
Summit Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for cancer. Its lead candidate is ivonescimab, a bispecific antibody designed to target both PD-1 and VEGF, two pathways involved in tumor growth and the immune response. The company is evaluating the treatment in clinical trials for multiple types of cancer. Summit licensed rights to develop and commercialize ivonescimab from China-based Akeso in 2022. Summit’s licensed territory covers markets outside China, including the United States, Canada, Europe and Japan.
Featured Articles
- Five stocks we like better than Summit Therapeutics
- Sandisk’s Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms
- Meta’s Access to Capital Remains Strong, But Borrowing Is Becoming More Expensive
- 3 Large-Cap Stocks Are Outperforming the S&P 500 Without AI Hype
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
